Market closed·Syncing…
Market closed · Close · 19 Nov

Syngene International Limited SYNGENEshare price and chart

Syngene International closed at ₹437.35 on 19 November 2026, up 0.59% on the day. The 52-week range is ₹344.45 to ₹678.95.

₹437.35The price one share last traded at, in rupees.+0.59% · ₹2.57
52-wk low ₹34428% up the rangeThe highest and lowest price the share has traded at in the past year, and where today's price sits between the two.high ₹679

Daily candlesEach candle is one trading day. The chart opens on the last year; drag back past the start or open full screen and the rest loads, back to listing (or the first day in our data). The body runs from the open to the close, the thin lines to the high and low. Green closed up, red closed down.

Loading prices…

Split and bonus adjusted daily candles. Drag back past the start, or open full screen, and its whole history loads. Scroll or pinch to zoom; full screen adds indicators, drawing and measuring.

Test a strategy on SYNGENE

Real prices, every charge counted. Pick one or write your own.
What Syngene International does
A short, human-reviewed summary of the business, written from public sources. Background, not analysis, and not updated intraday.
business summary

Majority owned by Biocon but separately listed on the NSE with its own public shareholders, Syngene does not sell any drugs of its own. It is a contract research, development and manufacturing organisation, running outsourced discovery labs and manufacturing plants on behalf of global pharmaceutical, biotech, agrochemical, animal health and nutrition companies, several of whom operate dedicated research centres inside Syngene's own facilities.

1
1Sector

Pharma - CRO/CDMO

2
2What it sells

Contract R&D and manufacturing services spanning drug discovery, pre-clinical and clinical development, and commercial-scale manufacturing of small molecules and biologics, plus dedicated research capacity built for specific clients.

3
3Who buys it

Large global pharmaceutical and biotech firms, including strategic partners such as Bristol-Myers Squibb, Baxter and Amgen, along with agrochemical, nutrition and animal health companies that outsource R&D and manufacturing rather than building it in-house.

4
4How it earns

Earns fees for scientific and manufacturing work performed for clients, either per project or through long-term dedicated-capacity contracts where a client funds part of a Syngene facility. Revenue depends on client R&D budgets and how many large multi-year contracts it holds.

Technical snapshotHow the share has been behaving: its momentum, its trend, how much of the trading was real buying to keep, and its returns.

EOD 19 Nov
RSI (14) · 30 oversold, 70 overboughtA score from 0 to 100 showing how strong recent up days were against recent down days.
63Neutral
0 oversold3070overbought 100
Delivery · bought to hold vs churnOf all the shares traded in a day, the share that actually changed hands and went into someone's demat account, rather than being bought and sold the same day.
48.5%Near average
today 48.5%20d avg 48.8%

The share of traded quantity that was actually delivered (not squared off intraday) - high delivery vs its 20-session average suggests real buying or holding, not just churn.

vs 50 DMAHow far today's close is above or below the average closing price of the last 50 trading days. It shows the medium-term trend.+11.7%vs 200 DMAHow far today's close is above or below the average closing price of the last 200 trading days, about ten months. It is the most watched line for the long-term trend.+4.4%1 monthHow much the share price has changed over the period.+16.2%3 monthsHow much the share price has changed over the period.+10.2%1 yearHow much the share price has changed over the period.▼ 34.0%Vol 30dHow much the share has actually been moving day to day, stated as a yearly percentage. 30% means it swung roughly 30% a year at that pace.50.8%

Returns and valuationWhat the market pays for this company and how well the business uses its money.

Books to 30 Sept 2026
Market capWhat the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality.₹17,654 Cr19 NovP/EHow many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit.94.5xlast 4 quarters, to Sept 2026Return on equityHow much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money.6.6%full year FY26Price to bookThe share price against the shareholders' money per share on the balance sheet. It asks what you pay for each rupee the owners have in the business.3.63xbooks of Sept 2026Return on capitalHow much operating profit the company made on all the money in the business, whether it came from owners or lenders.9.5%full year FY26EV / EBITDAWhat it would cost to buy the whole company, against the cash profit its business makes in a year. It is a P/E that ignores how the company is financed.18.8xDividend yieldThe cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share.0.29%last 12 monthsDebt to equityBorrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.0.01xbooks of Sept 2026FCF marginOf every ₹100 of sales, how much cash was left after running the business and paying for new assets.15.3%year to Mar 2026

Against its sectorWhere this company ranks among similar companies on each measure.

Healthcare Services · 49 peers · medians
P/EHow many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit.94.46vs 49.34 median
Cheapest: ONEGLOBAL 11.99Priciest: HCG 866.06
Net marginOf every ₹100 of sales, how much is left as profit after all costs, interest and tax.5.28%vs 11.48% median
Lowest: MAITREYA -7.51%Highest: 3BBLACKBIO 35.36%
Revenue growthHow much sales grew in the latest quarter against the same quarter a year earlier.-8.55%vs 23.64% median
Lowest: ONEGLOBAL -50.77%Highest: GKSL 194.62%

What the numbers sayShort plain statements about this company's latest figures.

Written by fixed rules

Latest quarterIn the quarter to September 2026 (results filed 27 Oct 2026), sales fell 8.6% from a year earlier to ₹833 cr and profit fell 52.0% to ₹32.2 cr.

Going well
  • Cash from operations was at least the reported profit in each of FY24, FY25, FY26.
Worth watching
  • Profit fell 2 years running (₹510 cr in FY24 to ₹317 cr in FY26).
Also changed
  • Foreign institutions cut their holding by 6.4 points over 5 quarters (16.50% to 10.14%).
  • Domestic institutions raised their holding by 5.2 points over 5 quarters (24.05% to 29.30%).

Each line is written by a fixed rule from the company's own filings and share price, and names the figures it uses. It describes what happened; it is not advice about the share.

Share price reaction to resultsWhat the share price did around each recent quarterly result.

Over the last 20 results, the share rose on 9 and fell on 11, and moved by 3% or more on 13.

+16%
-16%
Q2 FY23Q2 FY24Q2 FY25Q2 FY26Q2 FY27

Q2 FY27: results filed 27 Oct 2026. The share went from its close on 26 Oct 2026 to its close on 28 Oct 2026 +14.17%.

Dividend historyCash the company has paid per share, year by year.

₹290 / year
Paid 9 of 11 yrs
on ₹1 lakh at today's price · 0.29% yield · ₹1.25/share
What each year paid, on ₹1 lakh
114
114
114
229
286
286
286
286
17
18
19
20
21
22
23
24
25
26*
* 2026 so far - more may still be declared this year

2026 has paid ₹1.25 per share, about ₹286 on ₹1 lakh at today's price. It skipped 2 of the last 11 years. Earlier years are restated to today's share count, so a bonus or split never reads as a dividend cut. Dividends are at the company's discretion and can be cut or skipped.

What it has returnedThe yearly growth rate in the share price over each period, as if it had grown smoothly.

Price only, before dividends
+5.0%a year, over 10 years
1 yr
-31.1%
3 yr
-15.9%
5 yr
-6.3%
10 yr
+5.0%

Held for 10 years this compounded at +5.0% a year. The last twelve months were down -31.1%. Price only, before dividends.

Shareholding patternThe share of the company held by its promoters, by foreign and domestic institutions, and by the public, quarter by quarter.

Who owns it
52.59%promoter holding, as of 2026-09-30-17.8 pts since 2021
Promoter share since listing
2021-0952.59% now, drawn to its own range2026-09
Who owns it todayas of Sep 26
52.6%
29.3%
Promoter52.6%Foreign (FII)10.1%Domestic (DII)29.3%Public & others8.0%
Who is buying, who is leavingJun 25 to Sep 26
Promoter52.6%-0.1 pts
Foreign (FII)10.1%-6.4 pts
Domestic (DII)29.3%+5.3 pts

Each line is that holder's share of all shares over the last 6 quarters, drawn to its own scale - the printed change is the size of the move. Mutual funds and insurers sit inside the domestic figure; hover the bar above for that split.

The promoter/promoter-group stake as a percentage of total shares, each quarter since listing. A rising line means promoters are adding to their stake; a falling one often means dilution, pledge-driven sales, or stake sales to new investors.

Recent announcementsThe company's own filings to the exchange in the last six months: results, board meetings, investor calls and more, each with its source document.

Last 6 months
Analysts/Institutional Investor Meet/Con. Call Updates16-Nov-2026

Syngene International Limited has informed the Exchange about Schedule of meet

Analysts/Institutional Investor Meet/Con. Call Updates12-Nov-2026

Syngene International Limited has informed the Exchange about Schedule of meet

Analysts/Institutional Investor Meet/Con. Call Updates02-Nov-2026

Syngene International Limited has informed the Exchange about Transcript

Copy of Newspaper Publication29-Oct-2026

Syngene International Limited has informed the Exchange about Copy of Newspaper Publication

Analysts/Institutional Investor Meet/Con. Call Updates28-Oct-2026

Syngene International Limited has informed the Exchange about Link of Recording

Investor Presentation27-Oct-2026

Syngene International Limited has informed the Exchange about Investor Presentation

Resignation of Director/KMP/SMP27-Oct-2026

Syngene International Limited has informed the Exchange about Resignation of Director/KMP/SMP

Press Release27-Oct-2026

Syngene International Limited has informed the Exchange regarding a press release dated October 27, 2026, titled "Syngene reports sequential revenue growth of 13% in Q2 FY27; Operating EBITDA margin improves by 6 percentage points".

Change in Management27-Oct-2026

Syngene International Limited has informed the Exchange about change in Management

Outcome of Board Meeting27-Oct-2026

Syngene International Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

Analysts/Institutional Investor Meet/Con. Call Updates17-Oct-2026

Syngene International Limited has informed the Exchange about Schedule of meet

Certificate under SEBI (Depositories and Participants) Regulations, 201808-Oct-2026

Syngene International Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

Trading Window25-Sep-2026

Syngene International Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

General Updates24-Sep-2026

Syngene International Limited has informed the Exchange about Intimation of cancellation of meeting with Analyst/Institutional Investors

Resignation of Director/KMP/SMP21-Sep-2026

Syngene International Limited has informed the Exchange about Resignation of Director/KMP/SMP

Backtest idea · SYNGENEMACD momentum

Momentum turning up, only while the long trend is up.

BuyMACD crosses above signal, price above 200-day SMA
SellMACD crosses back below
Real prices · every charge countedRun on SYNGENE
Backtest idea · SYNGENELower band bounce

Buys a stretch below the usual range, sells on the way back.

BuyCloses below the lower Bollinger band
SellBack at the middle band, or 15 days
Real prices · every charge countedRun on SYNGENE
Backtest idea · SYNGENESupertrend rider

Stays in while the trend line says up, out when it flips.

BuySupertrend turns up
SellSupertrend turns down
Real prices · every charge countedRun on SYNGENE
Your own ideaWrite a rule for SYNGENE in plain English“Buy SYNGENE when …”
Start writing
Buy the dip on SYNGENEBuy when RSI(14) drops below 30
52-week high breakout on SYNGENEBuy when closes at a 52-week high
Golden cross on SYNGENEBuy when 50-day EMA crosses above 200-day
Stochastic oversold on SYNGENEBuy when stochastic %K drops below 20
Pullback in an uptrend on SYNGENEBuy when RSI(14) below 40, price above 200-day EMA

Key ratios at a glanceThe eight figures most people check first, each placed against companies in the same industry.

Against its sector
Market capWhat the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality.
₹17,654 cr
Larger than 82% of 49 peers
sector middle ₹2,819 cr
P/EHow many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit.
94.5x
Higher than 83% of 36 peers
sector middle 49.3x
Price to bookThe share price against the shareholders' money per share on the balance sheet. It asks what you pay for each rupee the owners have in the business.
3.6x
Lower than 71% of 45 peers
sector middle 5.4x
ROEHow much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money.
6.6%
Lower than 81% of 32 peers
sector middle 13.6%
FY23 12.8%FY26 6.6%
ROCEHow much operating profit the company made on all the money in the business, whether it came from owners or lenders.
9.5%
Lower than 76% of 38 peers
sector middle 16.0%
FY23 15.2%FY26 9.5%
Debt to equityBorrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.
0.01
Lower than 76% of 45 peers
sector middle 0.15
FY23 0.16FY26 0.00
Dividend yieldThe cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share.
0.3%
Higher than 80% of 49 peers
sector middle 0.0%
Sales growthHow much sales grew in the latest quarter against the same quarter a year earlier.
-8.6%
Lower than 94% of 36 peers
sector middle +23.6%
FY25 4.4%FY26 2.6%

Peers are the listed companies in the exchange's own industry group: Healthcare Research Analytics & Technology. Balance-sheet figures are from the latest filed balance sheet; trends show each financial year we hold.

Revenue and profit, year by yearSales and net profit by financial year or by quarter.

Sales and net profit
FY22FY24FY25FY26
SalesNet profitfell vs last yearEach on its own scale · hover a bar for its figures
Op. marginOf every ₹100 of sales, the profit from the main business before depreciation, interest and tax.24.6%FY26Profit YoYHow much net profit grew in the latest quarter against the same quarter a year earlier.▼ 52.0%latest quarterSalesMoney earned from selling the company's goods and services, before any costs. Also called revenue.₹3,739 CrFY26Net profitWhat is left for shareholders after all costs, interest and tax.₹317 CrFY26

Where every ₹100 of sales goesHow each ₹100 the company sold was spent, and how much stayed as profit.

FY26

In FY26, of every ₹100 of sales it kept ₹8.5 as profit. Other income added ₹1.9.

Where it wentPer ₹100 of sales
Running costs₹75.4Depreciation₹12.1Interest₹1.3Tax₹2.5Profit₹8.5Other items₹2.1
Profit per ₹100, year by year
FY22FY26

How fast it has grownCompound growth a year in sales and profit, over 3 and 5 financial years, beside the latest quarter.

Compounded a year
3 years5 yearsLatest qtr
Sales+12.8%-▼ 8.6%
Profit▼ 7.2%-▼ 52.0%
3 and 5 years are compounded a year across full financial years. The latest quarter is against the same quarter a year earlier.

Cash flowProfit is an accounting figure. Cash flow shows the money that really moved: in from the business, out on investments, and to or from lenders and shareholders.

Where the cash went

In FY26 cash fell by ₹139 Cr, after ₹344 Cr spent on plant and equipment.

FY26Cash in or out
Running the business+₹915 Cr
Investing-₹860 Cr
Lenders and shareholders-₹215 Cr
Net change in cash-₹139 Cr
Operating cash per ₹100 of profit
₹177FY23₹204FY24₹235FY25₹289FY26
₹100 or more means the reported profit arrived as cash.

Health check, year by yearMargins, returns and debt for each financial year, so you can see the direction.

MeasureFY24FY25FY26
Sales growthSales in this financial year against the previous one.·4.4%2.6%
Operating marginOf every ₹100 of sales, the profit from the main business before depreciation, interest and tax.29.1%28.6%24.6%
Net marginOf every ₹100 of sales in the year, how much was left as profit after everything.14.6%13.6%8.5%
ROEHow much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money.12.9%11.1%6.6%
ROCEHow much operating profit the company made on all the money in the business, whether it came from owners or lenders.15.6%15.4%9.5%
Debt to equityBorrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.0.03x0.03x0.00x
Interest coverHow many times the company's profit before interest could pay its interest bill.14.2x13.4x9.4x

Each row against this company's own usual level: green better, red worse, grey close to it.

Backtest idea · SYNGENEStochastic oversold

Buys when the close sits near the bottom of its recent range.

BuyStochastic %K drops below 20
Sell8% profit, or after 15 days
Real prices · every charge countedRun on SYNGENE
Backtest idea · SYNGENEPullback in an uptrend

Buys a pause inside a rising trend.

BuyRSI(14) below 40, price above 200-day EMA
Sell8% profit, or after 30 days
Real prices · every charge countedRun on SYNGENE
Backtest idea · SYNGENEBuy the dip

Buys after a sharp fall, betting on a bounce.

BuyRSI(14) drops below 30
Sell10% profit, or after 20 days
Real prices · every charge countedRun on SYNGENE
Backtest idea · SYNGENE52-week high breakout

Buys strength, when the price makes a new one-year high.

BuyCloses at a 52-week high
Sell8% stop loss
Real prices · every charge countedRun on SYNGENE
Backtest idea · SYNGENEGolden cross

Follows the long trend: in when the fast average crosses above the slow one.

Buy50-day EMA crosses above 200-day
SellWhen it crosses back below
Real prices · every charge countedRun on SYNGENE
MACD momentum on SYNGENEBuy when MACD crosses above signal, price above 200-day SMA
Lower band bounce on SYNGENEBuy when closes below the lower Bollinger band
Supertrend rider on SYNGENEBuy when supertrend turns up
Buy the dip on SYNGENEBuy when RSI(14) drops below 30
52-week high breakout on SYNGENEBuy when closes at a 52-week high

Peers side by sideCompanies in the same exchange-defined industry group, largest first. Tap a heading to sort.

Healthcare Services
CompanyWhat the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality.How many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit.The share price against the shareholders' money per share on the balance sheet. It asks what you pay for each rupee the owners have in the business.How much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money.How much operating profit the company made on all the money in the business, whether it came from owners or lenders.Borrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.Of every ₹100 of sales, how much is left as profit after all costs, interest and tax.How much sales grew in the latest quarter against the same quarter a year earlier.The cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share.
APOLLOHOSP
Apollo Hospitals Enterprise Limited
1.26 L cr56.0x11.8x21.5%20.7%0.508.4%+20.8%0.23%
MAXHEALTH
Max Healthcare Institute Limited
1.01 L cr73.3x8.9x14.3%14.4%0.3315.1%+20.3%0.19%
MANIPALHOS
Manipal Health Enterprises Limited
91,609 cr-5.5x--0.34--0.00%
ASTERDM
Aster DM Quality Care Limited
64,443 cr102.1x8.3x10.1%14.8%0.438.7%+136.3%0.41%
FORTIS
Fortis Healthcare Limited
61,140 cr58.9x5.8x11.0%13.5%0.2910.7%+17.3%0.12%
MEDANTA
Global Health Limited
39,747 cr64.2x9.2x15.0%17.9%0.1612.1%+33.6%0.03%
NH
Narayana Hrudayalaya Ltd.
38,279 cr44.3x7.7x19.7%16.0%0.998.4%+73.0%0.24%
LALPATHLAB
Dr. Lal Path Labs Ltd.
32,952 cr56.2x12.0x21.5%29.1%0.0019.4%+19.6%0.89%
KIMS
Krishna Institute of Medical Sciences Limited
32,248 cr147.1x8.2x9.7%9.9%0.834.3%+39.9%0.00%
SYNGENE
Syngene International Limited
17,654 cr94.5x3.6x6.6%9.5%0.015.3%-8.6%0.29%
AGARWALEYE
Dr. Agarwal's Health Care Limited
17,535 cr102.4x7.8x8.3%15.2%0.098.7%+31.4%0.00%
VIJAYA
Vijaya Diagnostic Centre Limited
15,559 cr76.3x14.7x19.7%30.3%0.0022.4%+26.7%0.13%
INDGN
Indegene Limited
15,552 cr37.7x4.6x13.9%18.9%0.009.9%+39.5%0.35%
RAINBOW
Rainbow Childrens Medicare Limited
12,602 cr43.1x7.3x17.9%27.8%0.0015.5%+23.2%0.28%
METROPOLIS
Metropolis Healthcare Limited
11,587 cr51.6x7.1x13.4%19.6%0.0112.7%+15.8%0.36%
YATHARTH
Yatharth Hospital & Trauma Care Services Limited
10,392 cr54.5x5.5x9.9%12.4%0.2412.2%+54.4%0.05%
PARKHOSPS
Park Medi World Limited
10,240 cr36.8x4.7x13.0%17.7%0.2014.7%-0.00%
JLHL
Jupiter Life Line Hospitals Limited
9,219 cr49.3x5.7x13.7%16.0%0.3611.4%+16.0%0.07%
HCG
Healthcare Global Enterprises Limited
9,181 cr866.1x6.8x1.9%9.4%0.520.8%+13.1%0.00%
THYROCARE
Thyrocare Technologies Limited
8,035 cr56.1x14.5x28.7%37.8%0.0015.4%+25.1%1.39%
SUVEN
Suven Life Sciences Limited
7,824 cr-17.3x-78.8%-78.8%0.00-+30.4%0.00%
NEPHROPLUS
Nephrocare Health Services Limited
6,455 cr49.4x5.4x6.9%13.4%0.0711.5%-0.00%
ARTEMISMED
Artemis Medicare Services Limited
5,370 cr46.8x5.4x11.6%14.8%0.2410.0%+13.2%0.13%
INDRAMEDCO
Indraprastha Medical Corporation Limited
3,303 cr17.2x4.1x27.5%37.7%0.0012.3%+8.3%1.11%
KMCSHIL
K M C Speciality Hospitals (India) Limited
3,288 cr53.8x----17.5%+24.1%0.00%
DRAGARWQ
Dr Agarwals Eye Hospital Limited
2,819 cr37.0x----15.3%+22.3%0.07%
VIMTALABS
Vimta Labs Limited
2,110 cr26.2x4.3x18.6%24.8%0.0318.7%+9.9%0.42%
SURAKSHA
Suraksha Diagnostic Limited
1,718 cr41.1x6.2x13.8%24.8%0.0211.9%+25.8%0.15%
KRSNAA
Krsnaa Diagnostics Limited
1,673 cr17.0x1.6x10.9%12.7%0.5711.1%+31.5%0.39%
SHALBY
Shalby Limited
1,317 cr34.3x1.3x3.5%6.7%0.533.2%+9.7%0.00%
GKSL
Gujarat Kidney And Super Speciality Limited
1,187 cr55.1x4.5x6.6%8.6%0.0616.2%+194.6%0.00%
3BBLACKBIO
3B Blackbio Dx Limited
1,130 cr19.1x----35.4%+42.4%0.38%
GPTHEALTH
GPT Healthcare Limited
1,087 cr20.9x3.8x16.3%23.1%0.0510.2%+14.1%0.76%
HEALTHX
Health X Platform Limited
867 cr-1.4x-0.2%-0.04-1.4%+60.7%0.00%
CREDENT
Credent Connect N Care Limited
860 cr-6.1x--0.15--0.00%
UNIHEALTH
Unihealth Hospitals Limited
774 cr-7.5x-16.2%0.13--0.00%
ONEGLOBAL
One Global Service Provider Limited
749 cr12.0x----14.1%-50.8%0.26%
GAUDIUMIVF
Gaudium IVF and Women Health Limited
724 cr28.7x4.4x16.1%20.4%0.0320.8%-0.00%
CHANDAN
Chandan Healthcare Limited
599 cr-3.5x-22.4%0.32--0.00%
MOMSBELIEF
Rays of Belief Limited
573 cr-3.8x--0.15--0.00%

Swipe the table sideways for more columns. Tap a heading to sort. A dash means the figure is not filed or cannot be worked out for that company. A bigger cohort is cut to its 40 largest companies.

Monthly price changeThe share's price change in every calendar month, one row per year, so you can check for yourself whether a month has a pattern.

Month by month
YearJanFebMarAprMayJunJulAugSepOctNovDecYear
2026
-27.3
-10.8
-7.7
+19.9
-5.5
-0.3
-12.4
+3.9
-8.8
+10.2
+8.6
·
-32.8%
11m
2025
-13.0
-12.6
+11.3
-12.7
+2.0
-1.2
+11.8
-12.3
-0.5
+4.4
-0.3
+0.4
-24.2%
2024
+7.0
-5.9
-0.5
-1.9
-2.5
+5.6
+13.8
+7.5
+3.4
-4.3
+9.4
-8.8
+22.4%
2023
-4.0
+3.3
+2.4
+13.9
+7.1
+5.5
+4.1
-2.8
+3.9
-15.4
+10.6
-6.8
+19.8%
2022
-8.0
-5.0
+10.3
+4.9
-8.7
-3.1
+2.4
+5.7
-6.7
+12.6
-3.8
-3.6
-5.5%
2021
-11.4
-1.3
-2.8
+1.9
+5.5
-0.2
+9.5
+0.4
-6.5
-9.8
+10.2
+4.0
-3.1%
2020
-1.9
-4.3
-20.1
+34.1
+10.9
+12.3
+21.6
-2.7
+16.6
-3.3
+8.0
+10.7
+99.8%
2019
+3.2
+2.1
+0.9
+3.1
+9.2
-0.3
-9.6
+2.5
+0.2
+6.9
-4.4
+1.0
+14.3%
2018
+10.8
-1.6
+1.2
+4.5
-3.9
+1.7
-2.4
-0.1
+1.0
-3.6
-6.7
+3.7
+3.5%
2017
-2.8
-7.9
+3.5
-0.8
-8.3
-0.7
+0.8
-6.0
+11.2
+2.0
+9.6
-2.3
-3.6%
Monthly movebelow -10%-10 to -5-5 to -2-2 to 00 to +2+2 to +5+5 to +10above +10%month in progress

Month-on-month change in closing price, adjusted for splits and bonuses but not for dividends, so a large dividend shows up here as a fall. Starts from 1995, when the exchange began trading equities, or from the stock's listing if later. This is a record of what happened, not a forecast.

Deals and filingsLarge trades reported to the exchange, plus the company's documents sorted by type.

DatePartySideQuantityPriceValue
2022-10-03ISHARES CORE MSCI EMERGING MARKETS ETF · blockBUY2,05,767₹560.60₹11.54 Cr
2022-10-03ISHARES CORE EMERGING MARKETS MAURITIUS CO · blockSELL2,05,767₹560.60₹11.54 Cr
2022-10-03ISHARES MSCI INDIA SMALL-CAP ETF · blockBUY26,735₹560.60₹1.50 Cr
2022-10-03ISHARES INDIA SC MAURITIUS COMPANY · blockSELL26,735₹560.60₹1.50 Cr
2018-05-16BIOCON LIMITED · bulkSELL15,56,326₹612.10₹95.26 Cr
2016-12-14SILVER LEAF OAK (MAURITIUS) LIMITED · bulkSELL12,00,000₹595.08₹71.41 Cr

The last two years of the company's filings to the exchange, grouped by the exchange's own categories. Each opens the original document.

Read enough? Test SYNGENE. “Buy SYNGENE when RSI(14) drops below 30, sell at 10% profit or after 20 days.” Real prices, every charge counted.

Run it free